- Home
- MRSN vs FGB Comparison
MRSN vs FGB Comparison
Compare MRSN & FGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- FGB
- Stock Information
- Founded
- MRSN 2001
- FGB 2007
- Country
- MRSN United States
- FGB United States
- Employees
- MRSN N/A
- FGB N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- FGB Finance/Investors Services
- Sector
- MRSN Health Care
- FGB Finance
- Exchange
- MRSN Nasdaq
- FGB Nasdaq
- Market Cap
- MRSN 71.9M
- FGB 65.1M
- IPO Year
- MRSN 2017
- FGB N/A
- Fundamental
- Price
- MRSN $0.53
- FGB $4.61
- Analyst Decision
- MRSN Buy
- FGB
- Analyst Count
- MRSN 7
- FGB 0
- Target Price
- MRSN $6.00
- FGB N/A
- AVG Volume (30 Days)
- MRSN 5.4M
- FGB 53.0K
- Earning Date
- MRSN 03-07-2025
- FGB 01-01-0001
- Dividend Yield
- MRSN N/A
- FGB 8.92%
- EPS Growth
- MRSN N/A
- FGB N/A
- EPS
- MRSN N/A
- FGB N/A
- Revenue
- MRSN $34,837,000.00
- FGB N/A
- Revenue This Year
- MRSN N/A
- FGB N/A
- Revenue Next Year
- MRSN N/A
- FGB N/A
- P/E Ratio
- MRSN N/A
- FGB N/A
- Revenue Growth
- MRSN N/A
- FGB N/A
- 52 Week Low
- MRSN $0.49
- FGB $2.85
- 52 Week High
- MRSN $6.28
- FGB $3.74
- Technical
- Relative Strength Index (RSI)
- MRSN 32.86
- FGB 67.16
- Support Level
- MRSN $0.56
- FGB $4.45
- Resistance Level
- MRSN $0.82
- FGB $4.55
- Average True Range (ATR)
- MRSN 0.07
- FGB 0.07
- MACD
- MRSN 0.03
- FGB 0.01
- Stochastic Oscillator
- MRSN 8.39
- FGB 87.64
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.